# Three Approvals, Three Different Bars Cleared

> Compare Semaglutide, Tirzepatide, and Tesamorelin — mypeptidesrx — A side-by-side comparison of three Research Peptide Fundamentals compounds — semaglutide, tirzepatide, and tesamorelin — across mechanism, approval breadth, evidence depth, administration, and the headline caution for each.

**RESEARCH PEPTIDE FUNDAMENTALS / MATRIX**

Semaglutide, tirzepatide, and tesamorelin are all FDA-approved and all began as peptide research — but 'approved' means something very different in each case. Here is the evidence base laid out plainly, not smoothed into one story.

## The short version

This page lines up [semaglutide](/semaglutide), [tirzepatide](/tirzepatide), and [tesamorelin](/tesamorelin) on the dimensions that actually distinguish them: what receptor each engages, how broad its approval is, how deep its trial record runs, and the one caution worth carrying forward from each compound's literature. The short version: all three are FDA-approved, but 'approved' spans a single-indication drug studied in a few hundred people (tesamorelin) to a five-indication drug studied in the tens of thousands (semaglutide). Reading the three side by side is the fastest way to see that 'this peptide is FDA-approved' is not, on its own, a very informative sentence. Nothing below is medical advice, and no dose is recommended for any individual.

## The comparison matrix

| Dimension | Semaglutide | Tirzepatide | Tesamorelin |
| --- | --- | --- | --- |
| Receptor / mechanism | GLP-1 receptor agonist (single incretin arm) | GIP/GLP-1 dual receptor agonist | GHRH receptor agonist (upstream of the incretin system) |
| Approved indications | Type 2 diabetes, chronic weight management, cardiovascular-risk reduction, kidney-event reduction, and (2025) MASH | Type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea | HIV-associated lipodystrophy only — no other approved indication |
| Deepest single trial | SELECT cardiovascular-outcomes trial, n=17,604 [3] | SURMOUNT-5 head-to-head vs. semaglutide, n=751 [1] | Pivotal Phase 3 approval trial, n=412 [15] |
| Most recent evidence cited here | FLOW kidney-outcomes trial, 2024, n=3,533 [2] | Pancreatitis/gallbladder meta-analysis, 2023, 9 RCTs, n=9,871 [7] | Body-composition meta-analysis, 2026, 5 pooled RCTs [10] |
| Headline caution | Cancer signals are flagged in its own safety review but explicitly not confirmed [5] | A statistically significant gallbladder/biliary-disease signal is confirmed in meta-analysis [7] | The approval does not extend past the one population it was studied in [11][15] |

## What 'approved' actually covers

'FDA-approved' is doing very different work in each of these three cases, and this is the single most important comparison on this page. Semaglutide's approval has widened steadily to cover five distinct clinical uses, each backed by its own dedicated trial: STEP for weight management [4], SELECT for cardiovascular risk [3], FLOW for kidney disease [2], plus diabetes and (2025) MASH. Tirzepatide's approval spans three indications — diabetes, weight management, and sleep apnea — each likewise trial-backed [1][6][8].

Tesamorelin's approval covers exactly one population: adults with HIV-associated lipodystrophy [11][15]. That is not a criticism of the compound — the trial evidence behind that one indication is genuinely solid, as the tesamorelin page details — but it means every other popular use of tesamorelin (general fat loss, anti-aging, athletic recovery) sits entirely outside what the FDA actually reviewed and approved. Treating 'FDA-approved' as interchangeable across these three compounds would flatten a real and clinically important distinction.

## Evidence depth

Depth separates these three as sharply as approval breadth does. Semaglutide's evidence spans multiple large randomized trials in the thousands to tens of thousands of participants, plus years of post-market pharmacovigilance [2][3][4][5]. Tirzepatide's trial program is smaller in trial count but comparably large per-trial, anchored by a direct superiority trial against the semaglutide standard [1][8][9] and a dedicated nine-trial safety meta-analysis [7]. Tesamorelin's entire evidence base, by contrast, is built from a smaller set of trials concentrated in one population: a 412-person pivotal trial, a 52-week extension program, and — as of 2026 — a five-trial pooled meta-analysis [10][14][15]. None of these bases is weak for what it claims to show; they simply do not claim to show the same amount.

## Administration and mechanism

All three require injection in their studied and approved forms — semaglutide is also available as a fasted-administration oral tablet, a formulation the other two do not have. Mechanistically, semaglutide and tirzepatide sit in the same family: both are incretin-receptor agonists that slow gastric emptying and act on hypothalamic appetite circuits, with tirzepatide adding a second receptor (GIP) to the same general strategy [6]. Tesamorelin works through an entirely separate axis — it stimulates the pituitary to release the body's own growth hormone rather than engaging gut-hormone receptors at all, which is why its side-effect profile and its cautions (IGF-1 elevation, malignancy contraindication) look nothing like the other two's gastrointestinal-dominated profile.

## The single caution worth remembering for each

For semaglutide: its own dedicated safety review is explicit that pancreatic- and thyroid-cancer signals exist in the data but occur too rarely to confirm or rule out — a genuinely unresolved question, not a dismissed one [5]. For tirzepatide: the confirmed finding is narrower and more concrete — a statistically significant increase in gallbladder or biliary disease across a nine-trial meta-analysis, even though the parallel pancreatitis fear did not hold up [7]. For tesamorelin: the caution is structural rather than a specific adverse event — its approval, however solid within its own population, simply does not extend to the uses it is most often discussed for [11][15]. Read together, the pattern across all three is the same: the strongest evidence and the widest popular use rarely line up perfectly, and this desk exists to keep that gap visible.

---

An independent research summary that reports evidence quality honestly, including where it's thin — not a clinic, not a pharmacy, not medical advice.